Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06WHY
|
|||
| Former ID |
DNC009585
|
|||
| Drug Name |
AZD-5438
|
|||
| Synonyms |
602306-29-6; AZD5438; AZD-5438; AZD 5438; 4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-N-(4-(methylsulfonyl)phenyl)pyrimidin-2-amine; CHEMBL488436; UNII-276Z913G29; MMV676604; 4-[2-METHYL-1-ISOPROPYL-1H-IMIDAZOL-5-YL]-N-[4-(METHYLSULFONYL)PHENYL]-2-PYRIMIDINAMINE; 2-Pyrimidinamine,4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-; 276Z913G29; 4-(2-methyl-3-propan-2-ylimidazol-4-yl)-N-(4-methylsulfonylphenyl)pyrimidin-2-amine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H21N5O2S
|
|||
| Canonical SMILES |
CC1=NC=C(N1C(C)C)C2=NC(=NC=C2)NC3=CC=C(C=C3)S(=O)(=O)C
|
|||
| InChI |
1S/C18H21N5O2S/c1-12(2)23-13(3)20-11-17(23)16-9-10-19-18(22-16)21-14-5-7-15(8-6-14)26(4,24)25/h5-12H,1-4H3,(H,19,21,22)
|
|||
| InChIKey |
WJRRGYBTGDJBFX-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 602306-29-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
26733716, 40162541, 46577688, 103589138, 104101719, 109692765, 123051130, 123124466, 124360785, 125164698, 125649588, 126646527, 126671311, 126731229, 134346790, 135262197, 135723837, 136340356, 136368076, 136920425, 143498613, 144115656, 152237513, 152258057, 152344093, 160646895, 162011563, 162038016, 162140080, 162202622, 165238063, 170495574, 172131335, 174007078, 174529963, 180371712, 184824934, 223399391, 223675677, 223704699, 223948759, 230957049, 241123037, 242060358, 247152154, 251971188, 252157678, 252160611, 252166682, 252214925
|
|||
| ChEBI ID |
CHEBI:91419
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8473). | |||
| REF 2 | AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. Mol Cancer Ther. 2009 Jul;8(7):1856-66. | |||
| REF 3 | AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells.Int J Radiat Oncol Biol Phys.2012 Nov 15;84(4):e507-14. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.